BA.2 update
From the technical briefing today:
www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings
"SGTP is now a reasonable proxy for BA.2 (accounting for 80% of
sequenced SGTP cases with an increasing trend). The proportion of SGTP cases is now
increasing. As of the 24 January 2022, the overall proportion of SGTP cases in England is 4.4%
compared to 2.2% on the 17 January. There is geographical variation with the highest
proportion in London (9.5%) and the lowest in the North-East region (0.9%).
Growth rate
BA.2 has an increased growth rate compared to BA.1 in all regions of England where there are
sufficient cases present to make an assessment. Whilst growth rates can be overestimates
early in the emergence of a variant, the apparent growth advantage is currently substantial.
Secondary attack rates
Analysis from routine contact tracing data indicated higher secondary attack rates amongst
contacts of BA.2 cases in households (13.4%; 95% CI: 10.7%-16.8%) than those for contacts of
other Omicron cases (10.3%; 95% CI: 10.1%-10.4%) in the period 27 December 2021 to 11
January 2022. These secondary attack rates are not adjusted for vaccination status and reflect
overall growth advantage rather than transmissibility.
Vaccine effectiveness
A preliminary assessment did not find evidence of a difference in vaccine effectiveness against
symptomatic disease for BA.2 compared to BA.1. However, numbers included in this study are
relatively small and it will be iterated. The University of Oxford has reported preliminary
unpublished pseudovirus neutralisation data. In this study, BA.1 and BA.2 pseudoviruses did
not differ substantially in neutralisation by sera from vaccinated individuals"
New risk assessment:
assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1051013/26-january-2022-risk-assessment-for-VUI-22JAN-01_BA.2.pdf